Physician profile
Ashaki Patel
NPI 1922505965
$4,229.43
in general payments reported to CMS, 2019-2025
22 companies · $2,577 in 2025
The $2,577 reported for 2025 was more than what 82% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $150 · 2023: $359 · 2024: $1,143 · 2025: $2,577.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,031 · Education: $40.19 · Travel and Lodging: $9.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,030.59 |
| Education | $40.19 |
| Travel and Lodging | $9.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $785.15 | 2023-2025 | |
| Janssen Biotech, INC. | $665.39 | 2024-2025 | Tremfya, Simponi Aria |
| Sun Pharmaceutical Industries INC. | $447.64 | 2023-2025 | Winlevi |
| Genzyme Corporation | $411.85 | 2024-2025 | |
| Galderma Laboratories, L.P. | $365.64 | 2023-2025 | Nemluvio, Aklief, Dysport |
| Regeneron Healthcare Solutions, INC. | $305.65 | 2024-2025 | Dupixent |
| Lilly USA, LLC | $187.73 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Pfizer INC. | $184.75 | 2024-2025 | |
| Arcutis Biotherapeutics, INC. | $165.46 | 2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $156.32 | 2024-2025 | |
| Allergan, INC. | $149.60 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $73.09 | 2023-2025 | Cabtreo, Arazlo |
| Amgen INC. | $71.13 | 2024 | Otezla |
| E.R. Squibb & Sons, L.L.C. | $68.32 | 2023-2024 | Sotyktu |
| Ucb, INC. | $41.92 | 2025 | Bimzelx |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.82 | 2023-2024 | Spevigo |
| Dermavant Sciences, INC. | $23.04 | 2023 | Vtama |
| Incyte Corporation | $22.41 | 2025 | Opzelura |
| Cipher Pharmaceuticals US LLC | $18.58 | 2025 | Natroba, Spinosad |
| Musculoskeletal Transplant Foundation INC. | $15.79 | 2024 | |
| Lnhc, INC | $14.60 | 2025 | Zelsuvmi |
| Journey Medical Corporation | $13.55 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashaki Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.